Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the importance of TGF-β-Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here, we examined pressure overload-induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload-induced fibrotic response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast-specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β-Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By contrast, cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ (refs. 19,39,40), IL-1β (ref. 41)) conditions.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“TGF-β1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
From A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, primary human cardiac fibroblasts, primary human dermal fibroblasts, and immortalized human cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ 20,33,34 , IL-1 β 35 ) conditions.”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF 20,33”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · cited 1×
“Heart failure is an increasingly prevalent disease characterized by reduced cardiac output resulting from a progressive loss of cardiomyocytes, ventricular chamber remodeling, and accumulation of interstitial fibrosis (1).”
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528 · cited 1×
“Global TGF-β activity is upregulated in diseased hearts, where one of its primary actions is directed at the resident fibroblasts to alter the fibrotic response and ventricular remodeling (47, 48).”
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jew082 · Cited by 2,425 · cited 1×
“The ratio of these measures ( E/e ′ ) was used as an indicator of diastolic function (60).”
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984 · cited 1×
“Progressive cardiac fibrosis in heart failure is predominantly mediated by the tissue-resident cardiac fibroblast, which becomes activated and then differentiated into a cell type referred to as the myofibroblast (5, 6).”
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934 · cited 1×
“TGF-β is considered a “master” cytokine/growth factor produced within injured or diseased tissues, where it activates fibroblasts and facilitates ECM production (15, 16).”
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Genetic lineage tracing defines myofibroblast origin and function in the injured heart
Kanisicak, O., Khalil, H., Ivey, M. J., Karch, J., Maliken, B. D., Correll, R. N., Brody, M. J., J. Lin, S.-C., Aronow, B. J., Tallquist, M. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12260 · Cited by 892 · cited 6×
“Hence, here we used mice in which the Postn genetic locus was targeted with a tamoxifen-inducible MerCreMer (MCM) cDNA (29), and these mice were crossed with Smad2 fl/fl , Smad3 fl/fl , Smad2/3 fl/fl , and Tgfbr1/2 fl/fl targeted mice (Figure 2A).”
InfluentialSelf-citation
Cited by
Items 301–400 of 925
Xu, C., Chen, J., Liang, L., Chen, S., Niu, X., Sang, R., Yang, C., & Rong, R. (2024) · Communications Biology · doi:10.1038/s42003-024-06154-0 · Cited by 30
BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy
Guo, M., Wang, H., & Chen, W. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.018 · Cited by 26
Human Adipocyte Conditioned Medium Promotes In Vitro Fibroblast Conversion to Myofibroblasts
El-Hattab, M. Y., Nagumo, Y., Gourronc, F. A., Klingelhutz, A. J., Ankrum, J. A., & Sander, E. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-67175-3 · Cited by 28
Microfibrillar-Associated Protein 4 Regulates Stress-Induced Cardiac Remodeling
Dorn, L. E., Lawrence, W. R., Petrosino, J. M., Xu, X., Hund, T. J., Whitson, B. A., Stratton, M. S., Janssen, P. M. L., Mohler, P. J., Schlosser, A. G., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317146 · Cited by 26
Li, F., Li, S.-S., Chen, H., Zhao, J., Hao, J., Liu, J., Zu, X., & Cui, W. (2021) · Aging · doi:10.18632/aging.203562 · Cited by 26
Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers
Dreyfuss, A. D., Velalopoulou, A. P., Avgousti, H., Bell, B. I., & Verginadis, I. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920867 · Cited by 29
“In turn, TGF-b differentiates the resident fibroblasts and bone marrow progenitors (111) into myofibroblasts and this event is considered a hallmark of RIHD-related fibrosis (74, 112–114).”
BackgroundModulation of anti-cardiac fibrosis immune responses by changing M2 macrophages into M1 macrophages
Chen, S., Wang, K., Fan, Z., Zhou, T., Li, R., Zhang, B., Chen, J., Chi, J., Wei, K., Liu, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00858-z · Cited by 26
Effects of chronic Porphyromonas gingivalis lipopolysaccharide infusion on skeletal muscles in mice
Kawamura, N., Ohnuki, Y., Matsuo, I., Suita, K., Ishikawa, M., Mototani, Y., Shiozawa, K., Ito, A., Yagisawa, Y., Hayakawa, Y., et al. (2019) · The Journal of Physiological Sciences · doi:10.1007/s12576-019-00670-z · Cited by 26
Epigenetic therapies in heart failure
Alexanian, M., Padmanabhan, A., McKinsey, T. A., & Haldar, S. M. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.04.012 · Cited by 27
Nakamura, Y., Kita, S., Tanaka, Y., Fukuda, S., Obata, Y., Okita, T., Kawachi, Y., Tsugawa-Shimizu, Y., Fujishima, Y., Nishizawa, H., et al. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00496.2019 · Cited by 26
Senavirathna, L. K., Huang, C., Pushparaj, S., Xu, D., & Liu, L. (2020) · Physiological Reports · doi:10.14814/phy2.14343 · Cited by 30
“…that TGFβ is a key regulator in fibroblast differentiation in fibrotic disorders in kidney, lung, heart, liver, and other organs (Bondi et al., 2010; Khalil et al., 2017; Pohlers et al., 2009; Thannickal et al., 2003; Webber, F I G U R E 9 HIF-1α and Smad3 silencing rescues the hypoxia and…”
BackgroundTan, W., Li, X., Zheng, S., Li, X., Zhang, X., Pyle, W. G., Chen, H., Wu, J., Sun, H., Zou, Y., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.677727 · Cited by 30
“In pressure overload, deletion of the genes encoding TGF-β receptor and SMAD3 reduces the fibrotic response; additionally, deletion of the TGF-β receptor reduces the hypertrophic response, whereas deletion of SMAD2/3 reduces cellular expansion (34).”
BackgroundCellular and Molecular Mechanisms of Hypertrophy of Ligamentum Flavum
Silwal, P., Nguyen-Thai, A. M., Alexander, P. G., Sowa, G., Vo, N. V., & Lee, J. Y. (2024) · Biomolecules · doi:10.3390/biom14101277 · Cited by 26
Wu, M., Guo, Y., Wu, Y., Xu, K., & Lin, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696472 · Cited by 28
“Current studies suggest that transforming growth factor-β1 (TGF-β1)/Smads signaling pathways play a pivotal role in the pathogenesis of postinfarction remodeling (Bujak and Frangogiannis 2007; Chen and Xie 2012; Khalil et al., 2017).”
BackgroundLiu, M., Peng, T., Hu, L., Wang, M., Guo, D. S., Qi, B., Ren, G., Wang, D., Li, Y., Song, L., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.77469 · Cited by 26
“Fibroblasts are the primary contributor to cardiac fibrosis, and HG is known to promote the activation and proliferation of fibroblasts [24, 25].”
Rypdal, K. B., Melleby, A. O., Robinson, E. L., Li, J., Palmero, S., Seifert, D. E., Martin, D., Clark, C., López, B., Andreassen, K. E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04361-1 · Cited by 28
Emodin in cardiovascular disease: The role and therapeutic potential
Guo, Y., Zhang, R., & Li, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1070567 · Cited by 30
“In addition, the activation of TGF-β and its signaling pathway is a major factor leading to fibrosis in several organs (Khalil et al., 2017).”
BackgroundDiversity of cells and signals in the cardiovascular system
Grandi, E., Navedo, M. F., Saucerman, J. J., Bers, D. M., Chiamvimonvat, N., Dixon, R. E., Dobrev, D., Gomez, A. M., Harraz, O. F., Hegyi, B., et al. (2023) · The Journal of Physiology · doi:10.1113/jp284011 · Cited by 26
“TGF-β , IL-6, IL-4 and IL-1) promotes the proliferation and activation of cardiac FBs, transforming them into a profibrotic phenotype (Guo et al., 2012; Kanellakis et al., 2012; Saxena et al., 2013; Khalil et al., 2017).”
BackgroundChalise, U., & Hale, T. M. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00401.2023 · Cited by 31
Cardiac fibroblasts in heart failure and regeneration
Harrington, A., & Moore‐Morris, T. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1388378 · Cited by 29
Brandt, M. M., Nguyen, I., Krebber, M. M., van de Wouw, J., Mokrý, M., Cramer, M. J., Duncker, D. J., Verhaar, M. C., Joles, J. A., & Cheng, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14542 · Cited by 31
Horváth, O., Ördög, K., Bruszt, K., Deres, L., Gallyas, F., Sümegi, B., Tóth, K., & Halmosi, R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1250858 · Cited by 25
Guan, C., Zhang, H., Wang, Y., Chen, Z.-T., Deng, B., Qiu, Q., Chen, S., Wu, M., Chen, Y., & Wang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5572088 · Cited by 25
“As we know, in vitro and in vivo evidences have shown that the TGF-β1-induced increase in ECM protein synthesis occurs mainly through the canonical Smad2/3 pathway [35, 36].”
BackgroundFu, G., Wang, Z., & Hu, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1323329 · Cited by 25
Insights into the post-translational modifications in heart failure
Zhang, X., Wang, Y., Li, H., Wang, D. W., & Chen, C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102467 · Cited by 28
Role of Gut Microbial Metabolites in Ischemic and Non-Ischemic Heart Failure
Hatamnejad, M. R., Medzikovic, L., Dehghanitafti, A., Rahman, B., Vadgama, A., & Eghbali, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052242 · Cited by 25
“…in non-ischemic HF include mitochondrial dysfunction [59] and the disruption of intracellular calcium homeostasis in cardiomyocytes [59,60], cardiac fibroblast-to-myofibroblast transition due to enhanced TGF-ß-SMAD signaling [61,62], as well as inflammatory responses in the myocardium [63].”
Li, C., Sun, J., Liu, Q., Dodlapati, S., Ming, H., Wang, L., Li, Y., Li, R., Jiang, Z., Francis, J., et al. (2021) · Epigenetics · doi:10.1080/15592294.2021.1982158 · Cited by 28
Self-citationLong-Chain and Very Long-Chain Ceramides Mediate Doxorubicin-Induced Toxicity and Fibrosis
Kretzschmar, T., Bekhite, M. M., Wu, J. M. F., Haase, D., Förster, M., Müller, T., Nietzsche, S., Westermann, M., Franz, M., Gräler, M. H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111852 · Cited by 27
Yang, X.-X., & Zhao, Z.-Y. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0280 · Cited by 24
Zhang, J., Zha, Y., Jiao, Y., Li, Y., Wang, J., & Zhang, S. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109266 · Cited by 26
Anwaier, G., Xie, T., Pan, C., Li, A.-Q., Yan, L., Wang, D., Chen, F.-K., Weng, D.-Z., Sun, K., Chang, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918335 · Cited by 24
“QSYQ and Its Main Ingredients Inhibits TGF-β1-Induced TGFβR II and Smads Protein Expression in RDF Myofibroblasts TGF-β1 binds to its type I (TGFβR I) and type II (TGFβR II) receptors, thereby triggering phosphorylation and nuclear translocation of Smad2 and Smad3 and inducing profibrotic gene transcription (Shi and M…”
BackgroundβIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function
Patel, N., Nassal, D. M., Greer-Short, A., Unudurthi, S. D., Scandling, B. W., Gratz, D. H., Xu, X., Kalyanasundaram, A., Fedorov, V. V., Accornero, F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131046 · Cited by 24
Forbes, T., Pauža, A. G., & Adams, J. C. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00251.2021 · Cited by 26
Leech extract alleviates idiopathic pulmonary fibrosis by TGF-β1/Smad3 signaling pathway
Zhang, Y., Lu, Y., Zhu, W.-J., Gong, X.-X., Qian, R., Lu, Y.-J., Yu, L., Yao, W.-F., Bao, B., Zhang, Y., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117737 · Cited by 25
Wen, J., Liu, K., Bu, Y., Zhang, Y., Zheng, Y., He, J., Huang, Y., Hu, D., & Wang, K. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122661 · Cited by 26
Thor: a platform for cell-level investigation of spatial transcriptomics and histology
Zhang, P., Chen, W., Tran, T. H., Zhou, M., Carter, K. N., Kandel, I., Li, S., Hoi, X. P., Sun, Y., Lai, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62593-1 · Cited by 33
Yan, T., Zhu, X., Zhang, X., Jia, X., Liu, J., Wang, X., Xiao, Y., Xiao, Z., Liu, T., & Dong, Y. J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154382 · Cited by 26
Seksaria, S., Mehan, S., Dutta, B. J., Gupta, G. D., Ganti, S. S., & Singh, A. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23330 · Cited by 24
Nelson, A. R., Christiansen, S. L. M., Naegle, K. M., & Saucerman, J. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303513121 · Cited by 23
“In injury signaling conditions, such as following myocardial infarction (MI), myocardial cells are exposed to elevated proinflammatory (16–18).”
Bradley, J., Spaletra, P. M., Li, Z., Sharp, T. E., Goodchild, T. T., Corral, L. G., Fung, L. M., Chan, K. W. H., Sullivan, R. W., Swindlehurst, C. A., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00603.2017 · Cited by 25
Activation of angiotensin II type-2 receptor protects against cigarette smoke-induced COPD
Mei, D. F., Tan, W. S. D., Liao, W., Heng, C. K. M., & Wong, W. S. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105223 · Cited by 23
“Both acute CS and chronic CS models markedly elevated TGF-β1 levels and upregulated the lung tissue levels of transcription factors Smad2 and Smad3 which mediate TGF-β1-induced signaling process [28,37].”
Cardiac fibroblast BAG3 regulates TGFBR2 signaling and fibrosis in dilated cardiomyopathy
Wang, B. Z., Morsink, M. A. J., Kim, S. W., Luo, L. J., Zhang, X., Soni, R. K., Lock, R. I., Rao, J., Kim, Y., Zhang, A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181630 · Cited by 23
“Previous work suggests that both are required for the activation of ACTA2 + myofibroblasts, which may explain the differences we encountered (13, 77).”
Yang, G., & Lin, C.-S. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/2016259 · Cited by 22
“Transforming growth factor beta receptor 1 (TGFBR1), a key molecule in TGFβ/smad signaling pathway [36], has been widely reported to modulate cellular processes in diseases [37].”
BackgroundTransforming Growth Factor-Beta in Skeletal Muscle Wasting
Klein, G. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031167 · Cited by 22
“[38], demonstrating in mouse experiments that selective deletion of TGF-β receptors 1 and 2, but not Smad 2/3, attenuated the cardiac hypertrophic response to overflow pressure stimulation.”
BackgroundHan, X., Wang, S., Yong, Z., Zhang, X., & Wang, X. (2022) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-022-09934-7 · Cited by 25
“The Smad-2/3 pathway is the major regulator of fibrotic responses in activated cardiac fibroblasts (Khalil et al., 2017).”
BackgroundWang, L., Li, L., Zhao, D., Yuan, H., Zhang, H., Chen, J., Pang, D., Lu, Y. W., & Ouyang, H. (2024) · Open Biology · doi:10.1098/rsob.230427 · Cited by 23
“TGF-β could transform cardiac fibroblasts to activated myofibroblasts in a Smad2/3-dependent way [13,30].”
BackgroundZhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117367 · Cited by 25
Stress Coping Strategies in the Heart: An Integrated View
Michalak, M., & Agellon, L. B. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00168 · Cited by 25
Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure
Preedy, M. E. J., Baliga, R. S., & Hobbs, A. J. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000724 · Cited by 25
Niro, F., Fernandes, S., Cassani, M., Apostolico, M., Cruz, J. O. L., Pereira-Sousa, D., Pagliari, S., Vinarský, V., Zdráhal, Z., Potěšil, D., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.07.003 · Cited by 22
Cytokine-Mediated Alterations of Human Cardiac Fibroblast’s Secretome
Bräuninger, H., Thottakara, T., Schön, J., Voss, S., Dhople, V. M., Warnke, S., Scherschel, K., Schrage, B., Kirchhof, P. F., Blankenberg, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212262 · Cited by 21
“Its translocation from cytoplasm to nucleus (Figure 3A) upon TGF-β stimulation has been shown in murine cardiac fibroblasts previously and is contributing to fibrosis [30,31].”
BackgroundCardiac fibrosis in oncologic therapies
Packard, R. R. S. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100575 · Cited by 23
Cheng, J., Xue, F., Cheng, C., Sui, W., Zhang, M., Qiao, L., Ma, J., Ji, X., Chen, W., Yu, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.997916 · Cited by 21
“was reported to promote fibroblast-to-myofibroblast transformation, and canonical TGF-β signaling upregulated Smad2/3 transcription factors thereby inducing cardiac fibrosis (Khalil et al., 2017).”
BackgroundSu, Y., Shi, D., Xia, G., Liu, Y., Xu, L., Dao, L., Lu, X., Shen, C., & Xu, C. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91396 · Cited by 22
“TGF-β-Smad2/3 signaling is well-documented for dominating myofibroblast activation and matrix protein synthesis 60-64 .”
Sacchi, M., Tomaselli, D., Ruggeri, M. L., Aiello, F. B., Sabella, P., Dore, S., Pinna, A., Mastropasqua, R., Nubile, M., & Agnifili, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052327 · Cited by 25
Yi, J.-S., Perla, S., Huang, Y., Mizuno, K., Giordano, F. J., Vinks, A. A. T. M. M., & Bennett, A. M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07169-z · Cited by 24
Yang, H., Sun, J., Yao, T., Li, Y., Xu, G., Zhang, C., Liu, X.-C., Zhou, W., Song, Q., Zhang, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.644886 · Cited by 23
“In CFs, inhibition of p38 by SB203580 inhibited the phosphorylation of NR4A1 and did not limit Smad3 phosphorylation, and blocking TGF-β signaling by LY2157299 and SB203580 could decrease the expression of α-SMA, collagen I and III.”
BackgroundInfluentialCarver, W. E., Fix, E., Fix, C., Fan, D., Chakrabarti, M., & Azhar, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30416 · Cited by 21
Li, Y., & Xu, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106049 · Cited by 21
Lu, Z., Zhang, Y., Yan, H., Su, Y., Guo, L., Liao, Y., Lu, T., Yu, H., Wang, L., Li, J., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01825-0 · Cited by 21
“The cytokine TGF-βmediates tissue fibrosis associated with inflammation and tissue injury, fibroblast-specific TGF-β-SMAD2/ 3 signaling underlies cardiac fibrosis [38].”
BackgroundPatricelli, C., Lehmann, P., Oxford, J. T., & Pu, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-46216-7 · Cited by 24
Algeciras, L., Palanca, A., Maestro, D., RuizdelRio, J., & Villar, A. V. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.06.003 · Cited by 22
Liao, R., Qi, Z., Tang, R. N., Wang, R., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714390 · Cited by 28
“Massive endeavors were made to relive or reverse myocardial fibrosis (Yang et al., 1999; Cunnington et al., 2009; Lei et al., 2011; Khalil et al., 2017), but the effect of those treatment strategies was failed because targeting TGF-β1, SMAD2/3, or TβRI/II directly will be ended up with poor outcomes like autoimmune di…”
BackgroundDai, Z., Cheng, J., Liu, B., Yi, D., Feng, A., Wang, T., An, L., Gao, C., Wang, Y., Zhu, M. M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022077 · Cited by 22
Tang, X., Liu, L., Liu, S., Song, S., & Li, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109275 · Cited by 22
The Role of MicroRNAs in Dilated Cardiomyopathy: New Insights for an Old Entity
Alonso-Villa, E., Bonet, F., Hernández‐Torres, F., Campuzano, Ó., Sarquella‐Brugada, G., Quezada-Feijoó, M., Ramos, M., Mangas, A., & Toro, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113573 · Cited by 20
Ruocco, G., Zoso, A., Mortati, L., Carmagnola, I., & Chiono, V. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00483 · Cited by 20
The role of heat shock proteins in the pathogenesis of heart failure (Review)
Sklifasovskaya, A. P., Blagonravov, M. L., Ryabinina, A., Goryachev, V. A., Syatkin, S. P., Chibisov, S. M., Akhmetova, K., Prokofiev, D. Y., & Agostinelli, E. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5309 · Cited by 22
Bai, Y.-H., Huang, L., Fan, Y., & Li, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202301773r · Cited by 20
“46 Previous studies have highlighted that Smad2/3 acts as a driver in the development and progression of a broad range of diseases, such as cardiac fibrosis, 47 idiopathic pulmonary fibrosis, 48 and kidney disease.”
BackgroundmiR-4739 mediates pleural fibrosis by targeting bone morphogenetic protein 7
Wang, M., Xiong, L., Jiang, L., Lu, Y., Liu, F., Song, L., Xiang, F., He, X., Yu, F., Shuai, S.-Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.057 · Cited by 20
Human Atrial Fibroblast Adaptation to Heterogeneities in Substrate Stiffness
Emig, R., Zgierski-Johnston, C. M., Beyersdorf, F., Rylski, B., Ravens, U., Weber, W., Kohl, P. K., Hörner, M., & Peyronnet, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01526 · Cited by 20
Paired box 6 inhibits cardiac fibroblast differentiation
Feng, Y., Li, M., Wang, S., Cong, W., Hu, G., Song, Y., Xiao, H., Dong, E., & Zhang, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.146 · Cited by 20
Salido-Medina, A. B., Gil, A., Expósito, V., Martínez, F., Redondo, J. M., Hurlé, M. A., Nistal, J. F., & García, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112910 · Cited by 21
“Myofibroblasts are contractile fibroblasts that produce large amounts of fibrotic extracellular matrix (ECM) molecules, whose pathological activation and persistence within tissues correlate with the progression of fibrotic diseases [45,46].”
BackgroundLi, M., Shu-Li, Z., Yuan, F., Han, H., Shao-Jun, L., Sheng-Xiong, T., Jia-Yu, T., Fang, X., & Dan, F. (2022) · Respiratory Research · doi:10.1186/s12931-022-02044-3 · Cited by 20
“A large number of studies have demonstrated the critical role of the TGF-β1/Smad2/3 signalling pathway in fibrosis [23, 24].”
BackgroundActivation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
Qiu, Z., Zhao, Y., Tian, T., Guo, W., Liu, R., Huang, J., & Xu, G. (2022) · Cells · doi:10.3390/cells11203184 · Cited by 21
“In the canonical pathway, TGF-β activates SMAD2/3 signaling, which in turn regulates the expressions of collagen and α-SMA in myofibroblasts [45].”
BackgroundSelf-citationWang, J., Bennett, D. S. Y., Echard, E. J., Chen, B., Ciampa, G., Zhao, W., Shi, Q., Yoon, J., Weiss, R. M., Grueter, C. E., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073937 · Cited by 21
The TGFβ superfamily in cardiac dysfunction
Wu, J., Jackson‐Weaver, O., & Xu, J. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy007 · Cited by 20
M10 peptide attenuates silica-induced pulmonary fibrosis by inhibiting Smad2 phosphorylation
Li, Y., Ji, X., Yao, W., Pan, H., Li, P., Liu, Y., Yuan, J., Xu, Q., & Ni, C. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.05.015 · Cited by 19
Cardiac Fibrosis Is a Risk Factor for Severe COVID-19
Mustroph, J., Hupf, J., Baier, M. J., Evert, K., Brochhausen, C., Broeker, K. A. E., Meindl, C., Seither, B., Jungbauer, C. G., Evert, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740260 · Cited by 21
“A hallmark of its development is increased fibroblast activation, which is caused by increased levels of transforming growth factor b1 (TGF-b1) (8).”
BackgroundInfluentialLiu, Q., Li, H., Wang, S., Huang, S., Yue, Y., Maihemuti, A., Zhang, Y., Huang, L., Luo, L., Feng, K., et al. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00014.2022 · Cited by 22
Heggli, I., Laux, C. J., Mengis, T., Karol, A. A., Cornaz, F., Herger, N., Aradi-Vegh, B., Widmer, J., Burkhard, M. D., Farshad‐Amacker, N. A., et al. (2022) · JOR Spine · doi:10.1002/jsp2.1237 · Cited by 23
“Third, several fibrosis-associated collagen subtypes were increased, that is, CO3A1 and CO6A1-3.(45,49,50) And fourth, α-SMA, the characteristic protein of fibrosis-associated myofibroblasts was upregulated.”
BackgroundCardiomyocyte-fibroblast crosstalk in the postnatal heart
Calderon, M. U., Gonzalez, B. A., & Yutzey, K. E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1163331 · Cited by 23
“In the adult heart after injury, Tgfβ signaling has well-established roles in the cardiac fibrotic response, including induction of pathologic activation of cardiac fibroblasts, and is the driving force for myofibroblast differentiation (Khalil et al., 2017).”
BackgroundTan, C. Y., Chan, P. S., Tan, H., Tan, S. W., Lee, C. J. M., Wang, J., Ye, S., Werner, H., Loh, Y. J., Lee, Y. L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04542-4 · Cited by 19
“Smad3 plays an essential role in heart remodelling in MI or TAC-induced heart failure models, although it plays different roles in CFs and CMs [41–43].”
BackgroundThrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease
Kimura, T., Iwadare, T., Wakabayashi, S., Kuldeep, S., Nakajima, T., Yamazaki, T., Aomura, D., Zafar, H., Iwaya, M., Joshita, S., et al. (2023) · Liver International · doi:10.1111/liv.15792 · Cited by 22
“It is well known that TGF β expresses collagen via the phosphorylation of SMAD2/3, 40 and so we investigated the association be-tween THBS2/TSP2 expression and SMAD in LX-2 cells.”
BackgroundJiang, W., Deng, B., Xie, M., Feng, Y., Jiang, X., Yang, B., Tan, Z., Ou, H., Tan, Y., Liu, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117012 · Cited by 19
Inflammation-induced fibrosis in skeletal muscle of female carriers of Duchenne muscular dystrophy
Preuße, C., von Moers, A., Kölbel, H., Pehl, D., Goebel, H., Schara, U., & Stenzel, W. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.05.003 · Cited by 19
Du, Y., Xiao, H., Wan, J., Wang, X., Li, T., Zheng, S., Feng, J., Ye, Q., Li, J., Li, G., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4607 · Cited by 19
“During fibrogenesis, Smad3, a major downstream mediator of TGF-β1, is phosphorylated by activated TGF-β type I receptor kinase (39-41).”
BackgroundPatel, N., Nassal, D. M., Gratz, D. H., & Hund, T. J. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1849145 · Cited by 20
Lotteau, S. J., Zhang, R., Hazan, A. T., Grabar, C., Gonzalez, D., Aynaszyan, S., Philipson, K. D., Ottolia, M., & Goldhaber, J. I. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019273 · Cited by 19
Intermittent prednisone treatment in mice promotes exercise tolerance in obesity through adiponectin
Quattrocelli, M., Wintzinger, M., Miz, K., Panta, M., Prabakaran, A. D., Barish, G. D., Chandel, N. S., & McNally, E. M. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211906 · Cited by 19
Liu, Y., Lu, H., Zhang, C., Hu, J., & Xu, D. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.01.005 · Cited by 20
Sun, J., Wang, Z., Shi, H., Gu, L., Wang, S., Wang, H., Li, Y., Wei, T., Wang, Q., & Wang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.175 · Cited by 19
Ikeda, M., Ide, T., Matsushima, S., Ikeda, S., Okabe, K., Ishikita, A., Tadokoro, T., Sada, M., Abe, K., Sato, M., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009366 · Cited by 22
Yokoe, S., Hayashi, T., Nakagawa, T., Kato, R., Ijiri, Y., Yamaguchi, T., Izumi, Y., Yoshiyama, M., & Asahi, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-01088-8 · Cited by 18
“With regard to fibrosis, activation of the transforming growth factor β (TGF-β)/Smad pathway has been reported as a prominent pathological feature of cardiac fibrosis [40, 41].”
BackgroundNicolini, G., Balzan, S., & Forini, F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121575 · Cited by 19
González‐Herrera, F., Catalán, M., Anfossi, R., Maya, J. D., Pedrozo, Z., Díaz-Araya, G., & Vivar, R. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110778 · Cited by 19
Decellularized heart extracellular matrix alleviates activation of hiPSC-derived cardiac fibroblasts
Kerr, C. M., Silver, S. E., Choi, Y. S., Floy, M. E., Bradshaw, A. D., Cho, S., Palecek, S. P., & Mei, Y. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.023 · Cited by 26
Russell‐Hallinan, A., Cappa, O., Kerrigan, L., Tonry, C. L., Edgar, K. S., Glezeva, N., Ledwidge, M. T., McDonald, K., Collier, P. H., Simpson, D. A. C., et al. (2024) · Cells · doi:10.3390/cells13090752 · Cited by 18
“Mechanistically, activation of cardiac fibroblasts by TGF β may deregulate the antioxidative capacity in the heart through GPX3 reduction by its action at the TGFR1 receptor rather than downstream Smad 2/3 signaling [38].”
BackgroundWang, K., Liu, C., Fang, B., Li, B., Li, Y., Xia, Q.-Q., Zhao, Y., Cheng, X.-L., Yang, S., Zhang, M., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107279 · Cited by 22
Structure, unique biological properties, and mechanisms of action of transforming growth factor β
Zelisko, N., Lesyk, R., & Стойка, Р. С. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107611 · Cited by 19
Metadata
- Authors
- Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., Karch, J., & Molkentin, J. D.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Molkentin, Jeffery D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-09-11
- Volume
- 127
- Issue
- 10
- Pages
- 3770-3783
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5617658
- OpenAlex
- W2750808153
- Cited by
- 905
- References
- 64
- Citations by year
- 2026: 92 · 2025: 102 · 2024: 128 · 2023: 121 · 2022: 144 · 2021: 110 · 2020: 84 · 2019: 85 · 2018: 34 · 2017: 2
- FWCI
- 43.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Civil War Book Review (submittedVersion)
- Language arts journal of Michigan (submittedVersion)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (158486, 148429)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01HL069779, R01HL105924)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060636)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, TGF-beta signaling, Smad2, Smad3, cardiac fibroblasts, myofibroblasts, TGF-beta receptor, pressure overload, cardiac hypertrophy, extracellular matrix remodeling
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Receptor, Transforming Growth Factor-beta Type II, Animals, Fibrosis, Heart Diseases, Male, Mice, Transgenic, Myocardium, Organ Specificity, Signal Transduction, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Gene Deletion, Receptors, Transforming Growth Factor beta, Myocytes, Cardiac, Mice, Smad2 Protein, Smad3 Protein, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.